| Trial Name: |
GOG 0188
|
| Intro: |
A Phase II Study of Faslodex® in Recurrent/Metastatic Endometrial Cancer |
| Condition: |
|
| Description: |
This study is being done to estimate the probability of clinical response to the drug Faslodex® in patients with persistent or recurrent endometrial cancer. The drug, Faslodex®, will be given intramuscularly (IM) every 28 days (1 cycle is defined as one IM injection of the drug). The minimum planned treatment period will be 2 cycles. |
| Criteria: |
- Patients must have a confirmed diagnosis of recurrent, persistent or metastatic endometrial cancer that is not curable with either surgery or radiation therapy
- Patients must have at least one “target lesion” to be used to assess response on this study as defined by RECIST
- Patients must have a GOG performance status of 0 or 1
- Patients must have adequate bone marrow, kidney, and liver function
- Patients may have received prior surgery, radiation therapy or hormonal treatment.
|
| Contact: |
For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422 |
Participant Confidentiality:
All information regarding participation in Clinical Trials is treated with the
utmost confidentiality. University Hospitals Case Medical Center and the
Division of Clinical Research recognize and respect the confidentiality of this
information. Access to information related to clinical trials and their
participants is restricted to authorized clinical trials personnel only.
Back